Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMID 17156143)

Published in Am J Gastroenterol on March 01, 2007

Authors

Spencer D Dorn1, Robert S Sandler

Author Affiliations

1: Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599-7080, USA.

Articles citing this

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65

Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. PLoS One (2013) 1.78

Increased pulse wave velocity and carotid intima-media thickness in patients with ulcerative colitis. Dig Dis Sci (2013) 1.45

Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci (2014) 1.26

Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease. J Inflamm (Lond) (2014) 1.00

Inflammatory bowel disease and thromboembolism. World J Gastroenterol (2014) 0.97

Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis (2013) 0.96

Arterial structure and function in inflammatory bowel disease. World J Gastroenterol (2015) 0.93

Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci (2012) 0.91

Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol (2013) 0.87

Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis (2014) 0.84

Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci (2010) 0.82

Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol (2016) 0.80

Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int J Med Sci (2011) 0.79

Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. Br J Clin Pharmacol (2011) 0.79

Inflammatory bowel disease as a risk factor for premature coronary artery disease. J Clin Med Res (2015) 0.78

Steroid exposure, acute coronary syndrome, and inflammatory bowel disease: insights into the inflammatory milieu. Am J Med (2014) 0.78

In Vivo Inflammation Does Not Impair ABCA1-Mediated Cholesterol Efflux Capacity of HDL. Cholesterol (2012) 0.78

Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets (2015) 0.77

Preventive health measures in inflammatory bowel disease. World J Gastroenterol (2016) 0.75

Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J Gastroenterol (2015) 0.75

Inflammatory and Lipid-Associated Markers of Cardiovascular Diseases in Children with First Exacerbation of Inflammatory Bowel Disease. Med Sci Monit (2016) 0.75

Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Dig Dis Sci (2015) 0.75

Articles by these authors

(truncated to the top 100)

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46

A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18

Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93

Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15

Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02

Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79

Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44

Clinical practice. Screening for colorectal cancer. N Engl J Med (2002) 3.43

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 3.35

Constipation and a low-fiber diet are not associated with diverticulosis. Clin Gastroenterol Hepatol (2013) 3.31

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst (2009) 3.15

A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology (2011) 3.03

Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol (2007) 2.94

The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol (2006) 2.93

A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med (2015) 2.88

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet (2008) 2.83

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 2.80

A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol (2002) 2.75

Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes (2010) 2.70

Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst (2009) 2.64

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43

RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22

Digestive and liver diseases statistics, 2004. Gastroenterology (2004) 2.14

A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol (2009) 2.14

Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res (2008) 2.13

Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol (2010) 2.10

Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J Epidemiol (2003) 2.06

Fusobacterium is associated with colorectal adenomas. PLoS One (2013) 1.99

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology (2012) 1.97

Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol (2013) 1.83

Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst (2003) 1.80

Patient time requirements for screening colonoscopy. Am J Gastroenterol (2007) 1.74

Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst (2007) 1.73

Editorial: colonoscopy and colorectal cancer mortality: strong beliefs or strong facts? Am J Gastroenterol (2010) 1.71

Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol (2013) 1.71

Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol (2008) 1.71

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70

Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70

Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology (2004) 1.70

Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. Dig Dis Sci (2010) 1.68

Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst (2004) 1.67

Reduced polyp detection as endoscopy shift progresses: experience with screening colonoscopy at a tertiary-care hospital. J Clin Gastroenterol (2011) 1.66

Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J (2012) 1.62

Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2005) 1.52

Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. Liver Transpl (2002) 1.52

Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. Am J Obstet Gynecol (2005) 1.49

Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev (2002) 1.48

Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg (2010) 1.48

Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol (2016) 1.47

Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev (2005) 1.45

Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. Med Decis Making (2008) 1.45

Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomarkers Prev (2004) 1.45

Research recruitment through US central cancer registries: balancing privacy and scientific issues. Am J Public Health (2006) 1.37

Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care (2013) 1.36

Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.33

Social ties and colorectal cancer screening among Blacks and Whites in North Carolina. Cancer Epidemiol Biomarkers Prev (2005) 1.31

Genetic heterogeneity in colorectal cancer associations between African and European americans. Gastroenterology (2010) 1.31

Associations of micronutrients with colon cancer risk in African Americans and whites: results from the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev (2003) 1.29

Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci (2012) 1.27

Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers. Int J Cancer (2006) 1.22

Impact of the 2008-2009 economic recession on screening colonoscopy utilization among the insured. Clin Gastroenterol Hepatol (2011) 1.21

Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology (2006) 1.21

Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology (2002) 1.20

Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis (2011) 1.17

Rural-urban differences in colon cancer risk in blacks and whites: the North Carolina Colon Cancer Study. J Rural Health (2006) 1.16

Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol (2003) 1.16

Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. BMC Health Serv Res (2010) 1.15

Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev (2005) 1.13

Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13

A diet high in fruits and low in meats reduces the risk of colorectal adenomas. J Nutr (2007) 1.11

Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst (2006) 1.11

Food groups and colon cancer risk in African-Americans and Caucasians. Int J Cancer (2004) 1.11

Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev (2002) 1.10

The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.10

Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. Carcinogenesis (2008) 1.10

Consumption of trans-fatty acid and its association with colorectal adenomas. Am J Epidemiol (2008) 1.06

Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. Cancer Epidemiol Biomarkers Prev (2010) 1.06

Dietary patterns, food groups, and rectal cancer risk in Whites and African-Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.05

Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol (2007) 1.05

UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res (2008) 1.05

Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. Am J Epidemiol (2010) 1.05

Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst (2009) 1.05

Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf (2013) 1.05

Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. Cancer Epidemiol Biomarkers Prev (2008) 1.05

Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.04

The association of physical activity and body mass index with the risk of large bowel polyps. Cancer Epidemiol Biomarkers Prev (2005) 1.04

Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis (2014) 1.03

Quality of colonoscopy reporting: a process of care study. Am J Gastroenterol (2002) 1.03

Gastrointestinal endoscopy nurse experience and polyp detection during screening colonoscopy. Clin Gastroenterol Hepatol (2008) 1.03

Patient perspectives on research recruitment through cancer registries. Cancer Causes Control (2005) 1.02

Race and colorectal cancer screening: a population-based study in North Carolina. N C Med J (2004) 1.02

Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control (2012) 1.02

COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control (2006) 1.01

Health behavior correlates among colon cancer survivors: NC STRIDES baseline results. Am J Health Behav (2006) 1.00

Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.00

A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev (2014) 0.99

Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer (2002) 0.98